1.Wicking Property of Graft Material Enhanced Bone Regeneration in the Ovariectomized Rat Model.
Seunghyun KIM ; Taeho AHN ; Myung Ho HAN ; Chunsik BAE ; Daniel S OH
Tissue Engineering and Regenerative Medicine 2018;15(4):503-510
BACKGROUND: Recruitment and homing cells into graft materials from host tissue is crucial for bone regeneration. METHODS: Highly porous, multi-level structural, hydroxyapatite bone void filler (HA-BVF) have been investigated to restore critical size bone defects. The aim was to investigate a feasibility of bone regeneration of synthetic HA-BVF compared to commercial xenograft (Bio-Oss). HA-BVF of 0.7 mm in average diameter was prepared via template coating method. Groups of animals (n = 6) were divided into two with normal (Sham) or induced osteoporotic conditions (Ovx). Subsequently, subdivided into three treated with HA-BVF as an experiment or Bio-Oss as a positive control or no treatment as a negative control (defect). The new bone formation was analyzed by micro-CT and histology. RESULTS: At 4 weeks post-surgery, new bone formation was initiated from all groups. At 8 weeks post-surgery, new bone formation in the HA-BVF groups was greater than Bio-Oss groups. Extraordinarily greater bone regeneration within the Ovx-HA group than Sham-Bio-Oss or Ovx-Bio-Oss group (p<0.05). CONCLUSION: This study suggests that the immediate wicking property of HA-BVF from host tissue activates a natural healing cascade without the addition of exogeneous factors or progenitor cells. HA-BVF may be an effective alternative for repairing bone defects under both normal and osteoporotic bone conditions.
Animals
;
Bone Regeneration*
;
Capillary Action*
;
Durapatite
;
Heterografts
;
Methods
;
Models, Animal*
;
Osteogenesis
;
Osteoporosis
;
Rats*
;
Stem Cells
;
Transplants*
2.Efficacy and Cardiovascular Safety of Romosozumab: A Meta-analysis and Systematic Review
Seo-Yong CHOI ; Jeong-Min KIM ; Sang-Hyeon OH ; Seunghyun CHEON ; Jee-Eun CHUNG
Korean Journal of Clinical Pharmacy 2023;33(2):128-134
Background:
This systematic review and meta-analysis aimed to evaluate the efficacy and cardiovascular safety of romosozumab compared with placebo.
Methods:
Randomized controlled trials (RCTs) were searched from Medline, EMBASE, Cochrane Central, and Web of Science until July 2022. Primary outcomes included the change in bone mineral density (BMD) from baseline at month 6. The secondary outcomes were the change of bone turnover markers (N-terminal propeptide of type 1 procollagen (P1NP); C-terminal telopeptide of type 1 collagen (CTX)) from baseline at month 3, and the incidence of cardiovascular adverse events for the total follow-up period.
Results:
A total of 7 RCTs on 8,370patients were included. Romosozumab showed better effects in improving BMD in both lumbar spine and femoral neck at month 6 (standardized mean difference, SMD 2.20 [95% CI: 1.89-2.52], SMD 0.63 [95% CI: 0.41-0.86]). In contrast to placebo, romosozumab significantly increased PINP levels and reduced CTX levels at month 3 (SMD 0.93 [95% CI: 0.65-1.22], SMD −1.03 [95% CI: −1.23~ −0.82]. However, there was no significant difference in the composite incidence of cardiovascular adverse events and major adverse cardiovascular events (OR 1.16 [95% CI: 0.82-1.65], OR 1.08 [95% CI: 0.75-1.56]).
Conclusion
This analysis showed that romosozumab significantly improved BMD compared to placebo and was beneficial for change in bone turnover markers. There is no significant difference in the incidence of cardiovascular adverse events compared to placebo.
3.Implementation of Pharmaceutical Care Services During the COVID-19 Pandemic Worldwide
So Yeon LEE ; Seunghyun CHEON ; Hye Won PARK ; Sang Hyeon OH ; Jee-Eun CHUNG ; Sook Hee AN
Korean Journal of Clinical Pharmacy 2024;34(4):242-251
Background:
This study sought to research the implementation of pharmaceutical care services and review the pharmaceutical care services used for coronavirus disease 2019 (COVID-19) prevention, diagnosis, therapy, and vaccination during the COVID-19 pandemic.
Methods:
All articles reporting pharmacists’ implementation of pharmaceutical care services during the COVID-19 pandemic were comprehensively searched in PubMed/Medline, Embase, and the Cochrane Library databases up toJuly 7, 2021, then included in this study. Twenty-four items of pharmaceutical care services were classified into the following 5categories: patient evaluation and monitoring, clinical decision support, compounding/dispensing/administration, patient consultation and education, and drug-related policy research and development.
Results:
A total of 674 articles from 100 countrieswere included, with the United States of America being the most frequently studied country. Across the 5 classified categories,compounding/dispensing/administration was most frequently examined (28.9%), followed by patient consultation and education (25.2%). Among the 24 items of pharmaceutical care services, medicine supply management was most frequently reported on (11.4%), followed by patient consultations (11.0%). The primary implemented pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination were public health education, COVID-19 testing services, medicine supply management, and vaccination, respectively.
Conclusion
Pharmacists have implemented diverse pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination globally. Further studies should be conducted to determine the correlation between the characteristics of healthcare accessibility in a country and the implemented pharmaceutical care services for COVID-19.
4.Implementation of Pharmaceutical Care Services During the COVID-19 Pandemic Worldwide
So Yeon LEE ; Seunghyun CHEON ; Hye Won PARK ; Sang Hyeon OH ; Jee-Eun CHUNG ; Sook Hee AN
Korean Journal of Clinical Pharmacy 2024;34(4):242-251
Background:
This study sought to research the implementation of pharmaceutical care services and review the pharmaceutical care services used for coronavirus disease 2019 (COVID-19) prevention, diagnosis, therapy, and vaccination during the COVID-19 pandemic.
Methods:
All articles reporting pharmacists’ implementation of pharmaceutical care services during the COVID-19 pandemic were comprehensively searched in PubMed/Medline, Embase, and the Cochrane Library databases up toJuly 7, 2021, then included in this study. Twenty-four items of pharmaceutical care services were classified into the following 5categories: patient evaluation and monitoring, clinical decision support, compounding/dispensing/administration, patient consultation and education, and drug-related policy research and development.
Results:
A total of 674 articles from 100 countrieswere included, with the United States of America being the most frequently studied country. Across the 5 classified categories,compounding/dispensing/administration was most frequently examined (28.9%), followed by patient consultation and education (25.2%). Among the 24 items of pharmaceutical care services, medicine supply management was most frequently reported on (11.4%), followed by patient consultations (11.0%). The primary implemented pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination were public health education, COVID-19 testing services, medicine supply management, and vaccination, respectively.
Conclusion
Pharmacists have implemented diverse pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination globally. Further studies should be conducted to determine the correlation between the characteristics of healthcare accessibility in a country and the implemented pharmaceutical care services for COVID-19.
5.Implementation of Pharmaceutical Care Services During the COVID-19 Pandemic Worldwide
So Yeon LEE ; Seunghyun CHEON ; Hye Won PARK ; Sang Hyeon OH ; Jee-Eun CHUNG ; Sook Hee AN
Korean Journal of Clinical Pharmacy 2024;34(4):242-251
Background:
This study sought to research the implementation of pharmaceutical care services and review the pharmaceutical care services used for coronavirus disease 2019 (COVID-19) prevention, diagnosis, therapy, and vaccination during the COVID-19 pandemic.
Methods:
All articles reporting pharmacists’ implementation of pharmaceutical care services during the COVID-19 pandemic were comprehensively searched in PubMed/Medline, Embase, and the Cochrane Library databases up toJuly 7, 2021, then included in this study. Twenty-four items of pharmaceutical care services were classified into the following 5categories: patient evaluation and monitoring, clinical decision support, compounding/dispensing/administration, patient consultation and education, and drug-related policy research and development.
Results:
A total of 674 articles from 100 countrieswere included, with the United States of America being the most frequently studied country. Across the 5 classified categories,compounding/dispensing/administration was most frequently examined (28.9%), followed by patient consultation and education (25.2%). Among the 24 items of pharmaceutical care services, medicine supply management was most frequently reported on (11.4%), followed by patient consultations (11.0%). The primary implemented pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination were public health education, COVID-19 testing services, medicine supply management, and vaccination, respectively.
Conclusion
Pharmacists have implemented diverse pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination globally. Further studies should be conducted to determine the correlation between the characteristics of healthcare accessibility in a country and the implemented pharmaceutical care services for COVID-19.
6.Implementation of Pharmaceutical Care Services During the COVID-19 Pandemic Worldwide
So Yeon LEE ; Seunghyun CHEON ; Hye Won PARK ; Sang Hyeon OH ; Jee-Eun CHUNG ; Sook Hee AN
Korean Journal of Clinical Pharmacy 2024;34(4):242-251
Background:
This study sought to research the implementation of pharmaceutical care services and review the pharmaceutical care services used for coronavirus disease 2019 (COVID-19) prevention, diagnosis, therapy, and vaccination during the COVID-19 pandemic.
Methods:
All articles reporting pharmacists’ implementation of pharmaceutical care services during the COVID-19 pandemic were comprehensively searched in PubMed/Medline, Embase, and the Cochrane Library databases up toJuly 7, 2021, then included in this study. Twenty-four items of pharmaceutical care services were classified into the following 5categories: patient evaluation and monitoring, clinical decision support, compounding/dispensing/administration, patient consultation and education, and drug-related policy research and development.
Results:
A total of 674 articles from 100 countrieswere included, with the United States of America being the most frequently studied country. Across the 5 classified categories,compounding/dispensing/administration was most frequently examined (28.9%), followed by patient consultation and education (25.2%). Among the 24 items of pharmaceutical care services, medicine supply management was most frequently reported on (11.4%), followed by patient consultations (11.0%). The primary implemented pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination were public health education, COVID-19 testing services, medicine supply management, and vaccination, respectively.
Conclusion
Pharmacists have implemented diverse pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination globally. Further studies should be conducted to determine the correlation between the characteristics of healthcare accessibility in a country and the implemented pharmaceutical care services for COVID-19.
7.Body Weight and Bone Density Changes in Patients with Ankylosing Spondylitis Receiving Anti-Tumor Necrosis Factor-alpha Treatment.
Jangwon LEE ; Minsuk JUNG ; Donghyun KIM ; Seunghyun LEE ; Sook Kyung OH ; Youngsun JO ; Sanghwan BYUN ; Kyoungmin NAM ; Choongwon LEE
Korean Journal of Medicine 2013;85(5):489-494
BACKGROUND/AIMS: To determine the changes in body weight and bone mineral density in patients with ankylosing spondylitis (AS) receiving anti-tumor necrosis factor-alpha (TNF-alpha) treatment. METHODS: Thirty-one patients with AS (25 males and 6 females) who fulfilled the Modified New York Criteria for AS were included in this retrospective study. All patients had active disease that eventually required anti-TNF-alpha treatment. Each patient received anti-TNF-alpha treatment (etanercept 25 mg twice weekly or adalimumab 40 mg twice monthly) for more than 2 years. Body weight, disease activity as Bath ankylosing spondylitis disease activity index (BASDAI), C-reactive protein, erythrocyte sedimentation rate (ESR), lumbar bone mineral density (LBMD), and femoral bone mineral density (FBMD) were measured at baseline and at 1 and 2 years after initiating anti-TNF-alpha treatment. RESULTS: There was a significant increase in mean body weight at 1 year (1.1 +/- 3.8 kg) and at 2 years (1.7 +/- 4.8 kg) compared with baseline. The gains in mean BMD of the lumbar spine were significant at 1 year (0.4 +/- 0.4) and 2 years (0.5 +/- 0.7) compared with baseline. Mean BMD of the femur was also increased at 1 year (0.08 +/- 0.7) and 2 years (0.1 +/- 0.8) compared with baseline, but these differences were not statistically significant. There were significant decreases in BASDAI at 1 year (-3.3 +/- 2.8) and at 2 years (-3.6 +/- 2.8) compared with baseline. CONCLUSIONS: This study showed significant increases in body weight, lumbar BMD, and BASDAI at 1 year and 2 years in patients with ankylosing spondylitis after receiving anti-TNF-alpha treatment.
Antibodies, Monoclonal, Humanized
;
Baths
;
Blood Sedimentation
;
Body Weight*
;
Bone Density*
;
C-Reactive Protein
;
Cachexia
;
Femur
;
Humans
;
Male
;
Necrosis*
;
Retrospective Studies
;
Spine
;
Spondylitis
;
Spondylitis, Ankylosing*
;
Adalimumab
8.Body Weight and Bone Density Changes in Patients with Ankylosing Spondylitis Receiving Anti-Tumor Necrosis Factor-alpha Treatment.
Jangwon LEE ; Minsuk JUNG ; Donghyun KIM ; Seunghyun LEE ; Sook Kyung OH ; Youngsun JO ; Sanghwan BYUN ; Kyoungmin NAM ; Choongwon LEE
Korean Journal of Medicine 2013;85(5):489-494
BACKGROUND/AIMS: To determine the changes in body weight and bone mineral density in patients with ankylosing spondylitis (AS) receiving anti-tumor necrosis factor-alpha (TNF-alpha) treatment. METHODS: Thirty-one patients with AS (25 males and 6 females) who fulfilled the Modified New York Criteria for AS were included in this retrospective study. All patients had active disease that eventually required anti-TNF-alpha treatment. Each patient received anti-TNF-alpha treatment (etanercept 25 mg twice weekly or adalimumab 40 mg twice monthly) for more than 2 years. Body weight, disease activity as Bath ankylosing spondylitis disease activity index (BASDAI), C-reactive protein, erythrocyte sedimentation rate (ESR), lumbar bone mineral density (LBMD), and femoral bone mineral density (FBMD) were measured at baseline and at 1 and 2 years after initiating anti-TNF-alpha treatment. RESULTS: There was a significant increase in mean body weight at 1 year (1.1 +/- 3.8 kg) and at 2 years (1.7 +/- 4.8 kg) compared with baseline. The gains in mean BMD of the lumbar spine were significant at 1 year (0.4 +/- 0.4) and 2 years (0.5 +/- 0.7) compared with baseline. Mean BMD of the femur was also increased at 1 year (0.08 +/- 0.7) and 2 years (0.1 +/- 0.8) compared with baseline, but these differences were not statistically significant. There were significant decreases in BASDAI at 1 year (-3.3 +/- 2.8) and at 2 years (-3.6 +/- 2.8) compared with baseline. CONCLUSIONS: This study showed significant increases in body weight, lumbar BMD, and BASDAI at 1 year and 2 years in patients with ankylosing spondylitis after receiving anti-TNF-alpha treatment.
Antibodies, Monoclonal, Humanized
;
Baths
;
Blood Sedimentation
;
Body Weight*
;
Bone Density*
;
C-Reactive Protein
;
Cachexia
;
Femur
;
Humans
;
Male
;
Necrosis*
;
Retrospective Studies
;
Spine
;
Spondylitis
;
Spondylitis, Ankylosing*
;
Adalimumab
9.A Case of Gigantic Ectasia of Right Coronary Artery Associated with Acute Myocardial Infarction.
Jung Rae CHO ; Hee Doo KYUNG ; Sung Jin OH ; Joohyuk SOHN ; Seunghyun KWON ; Ju Young YANG ; Won Heum SHIM
Korean Circulation Journal 2002;32(2):179-184
Coronary artery ectasia is an uncommon disorder diagnosed in 1 to 4% of patients undergoing coronary arteriography. Coronary artery ectasia is often considered a variant of atherosclerotic coronary artery disease, although other causes should be considered. Complications from this disease usually occur as thrombo-embolic phenomena primarily due to thrombosis in the ectatic segment of the coronary artery. A 53-year old man was transferred to our ER, presenting with acute inferior wall infarction. Coronary angiogram showed a gigantic ectatic right coronary artery (RCA) with occlusion of the mid portion by a huge mural thrombus. We injected and infused glycoprotein IIb-IIIa inhibitor in the RCA, however the lysis of thrombus was minimal. Subsequently, we infused Urokinase into the RCA for 2 days. Follow-up angiography revealed partial lysis of the thrombus. The patient demonstrated no thrombo-embolic events during two months of coumadinization, and follow-up angiography revealed a complete lysis of the thrombus.
Angiography
;
Coronary Artery Disease
;
Coronary Vessels*
;
Dilatation, Pathologic*
;
Follow-Up Studies
;
Glycoproteins
;
Humans
;
Infarction
;
Middle Aged
;
Myocardial Infarction*
;
Thrombosis
;
Urokinase-Type Plasminogen Activator
;
Warfarin
10.A Case of Immune Thrombocytopenic Purpura Accompanying Ulcerative Colitis.
Hyun Tae KIM ; Tae Oh KIM ; Hyung Jun KIM ; Soon Il LEE ; Gi Jung JEON ; Eun Ji LEE ; Seunghyun PARK ; Taehoon NO
The Korean Journal of Gastroenterology 2014;64(4):234-238
Ulcerative colitis (UC) is a chronic idiopathic inflammatory disorder of the colon with a variable clinical course of exacerbation and remission. Extraintestinal manifestations of UC, including hematological disorders, such as the rare immune thrombocytopenic purpura (ITP), may be the presenting symptoms. We encountered the case of a 23-year-old man with UC who showed typical symptoms and endoscopic findings. Despite receiving steroid treatment, the patient developed severe thrombocytopenia. He was diagnosed with ITP, characterized by autoimmunity, a demonstrated low platelet count, normal bone marrow, positivity for autoantibody to platelet membrane antigen, and no splenomegaly. We initiated high dose intravenous immunoglobulin immediately for treatment of his steroid-refractory thrombocytopenia. The patient's hematochezia and platelet count improved following immunoglobulin treatment. After discharge, the patient's platelet count was maintained at a stable level and his condition was good. This case suggests that immunoglobulin therapy may be useful for treatment of ITP in UC.
Autoimmunity
;
Blood Platelets
;
Bone Marrow
;
Colitis, Ulcerative*
;
Colon
;
Gastrointestinal Hemorrhage
;
Humans
;
Immunization, Passive
;
Immunoglobulins
;
Membranes
;
Platelet Count
;
Purpura, Thrombocytopenic, Idiopathic*
;
Splenomegaly
;
Thrombocytopenia
;
Young Adult